Last reviewed 2026-04-19 · How we verify

Metaclopramide

At a glance

Approved indications

• Chemotherapy-induced nausea and vomiting
• Diabetic gastroparesis
• Gastroesophageal reflux disease
• Gastrointestinal Radiography Adjunct
• Intubation of gastrointestinal tract
• Prevention of Post-Operative Nausea and Vomiting

Common side effects

No common side effects on file.

Key clinical trials

• The Effect of Prucalopride on Gastric Emptying in Intensive Care Unit Patients (Phase 1)
• A Standardized Intervention to Improve the Management of Chemotherapy-induced Nausea and Vomiting in Patients With Head and Neck Squamous Cell Carcinomas (NA)
• Quality of Recovery After Laparoscopic Cholecystectomy: A Prospective, Randomised, Controlled Trial Comparing Opioid Free Multimodal Analgesia Versus Opioid Based Anesthesia (NA)
• Eptinezumab as an Adjunct to Standard of Care for MIGRANE in an Acute EmeRgency Context (Migraine ERase Study) (Phase 3)
• Metoclopramide vs Placebo for Prevention of Pneumonia in Acute Stroke Patients Fed Via Nasogastric Tubes (Phase 4)
• MEtoclopramide, DExamethasone or Axoli (Palonoseton) for the Prevention of Delayed Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy: the MEDEA-trial (Phase 3)
• Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting (Phase 3)
• High Protein Intake During the Early Phase of Critical Illness Compared With Normal Protein Intake (N/A)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Metaclopramide CI brief — competitive landscape report
• Metaclopramide updates RSS · CI watch RSS
• Institute of Liver and Biliary Sciences, India portfolio CI